<DOC>
	<DOCNO>NCT00534417</DOCNO>
	<brief_summary>The purpose study determine combination continuous daily capecitabine fulvestrant load dose schedule delay disease progression metastatic breast cancer ( MBC ) patient .</brief_summary>
	<brief_title>Phase II Trial Capecitabine With Fulvestrant Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<criteria>Provide write informed consent prior studyspecific screening procedure , understand patient right withdraw study time , without prejudice . At least 18 year age . Postmenopausal female ( ie , amenorrheic least 12 month prior study entry ) . Postmenopausal status confirm draw follicle stimulate hormone ( FSH ) estradiol level &lt; 2 year since last menses . Ambulatory outpatient Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 study entry . Primary tumor human epidermal growth factor receptor 2 ( HER2 ) negative study entry . ( Investigator discretion use instance immunohistochemistry [ IHC ] 2+ . ) Histologically cytologically confirm MBC . Primary tumor and/or metastatic lesion estrogen receptor + and/or progesterone receptor + IHC . At least one measurable evaluable ( nonmeasurable ) lesion accord Response Evaluation Criteria Solid Tumors ( RECIST ) criterion ( see Appendix 11.6 ) irradiate ( i.e. , newly arise lesion previously irradiate area accept ) . Ascites , pleural effusion , bone metastasis consider measurable consider evaluable ( nonmeasurable ) . Minimum indicator lesion size measurable disease : ≥10 mm measure spiral compute tomography ( CT ) ≥20 mm measure conventional technique . Adequate hematologic , renal , hepatic function . Hematologic value : Neutrophils ( ANC ) &gt; 1.5 x 109/L ; Platelet count &gt; 100 x 109/L . Renal function : estimate creatinine clearance &gt; 30 mL/min calculate CockcroftGault equation . Note : In patient moderate renal impairment ( calculated creatinine clearance 30 50 mL/min ) baseline , dose reduction ( 1 ) capecitabine start dose require . Serum bilirubin &lt; 1.5 x upper limit normal ( ULN ) . Alanine transaminase ( ALT ) aspartate transaminase ( AST ) &lt; 2.5 x ULN ( &lt; 5 x ULN case liver metastasis ) . Alkaline phosphatase &lt; 2.5 x ULN ( &lt; 5 x ULN case liver metastases &lt; 10 x ULN case bone disease ) . International normalization ratio ( INR ) &lt; 1.6 . Must ≤ 1 prior regimen endocrine therapy metastatic breast cancer . This would include patient recurrence adjuvant hormone therapy OR first recurrence adjuvant hormone therapy OR progress first line hormone therapy metastatic breast cancer OR treatment naïve patient present metastatic breast cancer . Prior administration capecitabine . Prior administration fulvestrant . Prior chemotherapy metastatic breast cancer . Radiotherapy ≤ 2 week prior registration , except nontarget lesion singledose radiation palliation . NOTE : Prior radiation target lesion ( ) permit clear progression lesion since radiation complete . Life expectancy &lt; 3 month . Serious , uncontrolled , concurrent infection ( ) . Prior unanticipated severe reaction fluoropyrimidine therapy , know hypersensitivity 5fluorouracil know dihydropyrimidine dehydrogenase ( DPD ) deficiency . Treatment carcinoma within last 5 year , except cure nonmelanoma skin treat insitu cervical cancer superficial bladder tumor ( stage Ta Tis ) . Participation investigational drug study within 4 week precede start study treatment . Clinically significant cardiac disease ( e.g. , congestive heart failure , symptomatic coronary artery disease cardiac arrhythmia well controlled medication ) myocardial infarction within last 12 month prior study entry . Active brain metastasis . Patients neurological symptom must undergo CT scan magnetic resonance imaging ( MRI ) brain exclude active brain metastasis . NOTE : Patients treat brain metastasis eligible provide evidence disease definitive therapy ( include steroid ) ≥ 3 month prior study entry . Central nervous system ( CNS ) disorder psychiatric disability judge investigator clinically significant , preclude informed consent , interfere compliance oral drug intake . Known human immunodeficiency virus chronic hepatitis B C. Other serious uncontrolled medical condition investigator feel might compromise study participation . Major surgery within 4 week start study treatment , without complete recovery . Lack physical integrity upper GI tract malabsorption syndrome . Known , exist uncontrolled coagulopathy . Any following laboratory value : Abnormal hematologic value ( neutrophils [ ANC ] : &lt; 1.5 × 109/L , platelet count : &lt; 100 × 109/L ) Impaired renal function ( estimate creatinine clearance : &lt; 30 mL/min calculate CockcroftGault equation ) . Note : In patient moderate renal impairment ( calculated creatinine clearance : 30 50 mL/min ) baseline , dose reduction ( 1 ) capecitabine start dose require . Serum bilirubin &gt; 1.5 × upper normal limit ( ULN ) . Alanine transaminase ( ALT ) aspartate transaminase ( AST ) &gt; 2.5 × ULN ( &gt; 5 × ULN case liver metastasis ) . Alkaline phosphatase &gt; 2.5 × ULN ( &gt; 5 × ULN case liver metastases &gt; 10 × ULN case bone disease ) . International normalization ratio ( INR ) &gt; 1.6 . History : Bleeding diathesis , ( ie , disseminate intravascular coagulation [ DIC ] , clot factor deficiency ) Longterm anticoagulant therapy , ( antiplatelet therapy warfarin 1 mg qd port prophylaxis ) . History hypersensitivity active inactive excipients fulvestrant ( ie , castor oil Mannitol ) . Unwillingness give write informed consent . Unwillingness participate inability comply protocol duration study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Hormone</keyword>
	<keyword>Receptor</keyword>
	<keyword>Positive</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Breast</keyword>
	<keyword>Cancer</keyword>
</DOC>